BCAX

Company Overview — What Does Bicara Therapeutics Inc. Do?

We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-ß. Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-ß signaling within the tumor microenvironment, or TME. Ficerafusp alfa directs the TGF-ß inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will lead to durable responses and an increase in overall survival, or OS, while reducing the adverse effects typically associated with systemic TGF-ß inhibition. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic, or R/M, HNSCC excluding patients associated with human papillomavirus infection, or HPV-positive patients, with oropharyngeal squamous cell carcinoma, or OPSCC, late in the fourth quarter of 2024 or early in the first quarter of 2025. We are conducting an ongoing Phase 1/1b trial of ficerafusp alfa in the U.S., which includes a cohort of HNSCC patients who were treatment-naïve in the R/M setting. In this cohort, treatment with ficerafusp alfa in combination with pembrolizumab resulted in a 54% (21/39) overall response rate, or ORR, in the efficacy evaluable population, and a 64% (18/28) ORR in patients not associated with human papillomavirus infection, or HPV-negative patients. The historical response rate observed in a Phase 3 trial with pembrolizumab monotherapy, the current standard of care in R/M HNSCC, was 19%. Furthermore, treatment with ficerafusp alfa in combination with pembrolizumab demonstrated an 18% (5/28) complete response rate, or CR rate, and a median progression-free survival, or mPFS, of 9.8 months in HPV-negative patients. With at least 12 months of follow-up, median OS and median duration of response, or mDOR, have not yet been reached, and we expect to announce updated interim Phase 1/1b data at future medical meetings in 2025. Based on the clinical data generated to date, we believe that ficerafusp alfa in combination with pembrolizumab has the potential to become a first-line standard of care therapy in HPV-negative R/M HNSCC. We also believe ficerafusp alfa has the potential to provide meaningful clinical benefit in other solid tumors where there is a strong biologic rationale for the dual inhibition of both EGFR and TGF-ß, such as colorectal cancer and other squamous cell carcinomas which typically overexpress EGFR and TGF-ß pathways. We have demonstrated preliminary activity of ficerafusp alfa in combination with pembrolizumab or as a monotherapy across several squamous cell carcinomas, including cutaneous squamous cell carcinoma, or CSCC. Within our Phase 1/1b dose expansion cohorts conducted in the U.S. and Canada, we have observed to date a preliminary 42% (5/12) ORR with ficerafusp alfa monotherapy in relapsed and/or refractory CSCC patients. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the TME and limits systemic toxicity. This approach was deployed in the development of ficerafusp alfa, where we believe the bifunctional design can improve upon the therapeutic profile of immunotherapies and targeted therapies by addressing resistance mechanisms and limiting off-target toxicity, therefore, enhancing the treatment effect and tolerability for targeted patient populations with cancer. We were incorporated under the laws of the State of Delaware on December 12, 2018 under the name “Bicara Therapeutics Inc.” Our principal corporate office is located at 116 Huntington Avenue, Suite 703, Boston, MA 02116, and our telephone number is 617-468-4219. We have one subsidiary, Bicara Securities Corporation, formed in October 2023 under the laws of the Commonwealth of Massachusetts. Bicara Therapeutics Inc. (BCAX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Claire Mazumdar, headquartered in CAMBRIDGE, Massachusetts. With a market capitalization of $1.3B, BCAX is one of the notable companies in the Healthcare sector.

Bicara Therapeutics Inc. (BCAX) Stock Rating — Hold (April 2026)

As of April 2026, Bicara Therapeutics Inc. receives a Hold rating with a composite score of 32.8/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.BCAX ranks #1,422 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Bicara Therapeutics Inc. ranks #118 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

BCAX Stock Price and 52-Week Range

Bicara Therapeutics Inc. (BCAX) currently trades at $21.31. The stock lost $0.67 (3.0%) in the most recent trading session. The 52-week high for BCAX is $20.25, which means the stock is currently trading 5.2% from its annual peak. The 52-week low is $7.80, putting the stock 173.2% above its annual trough. Recent trading volume was 283K shares, suggesting relatively thin trading activity.

Is BCAX Overvalued or Undervalued? — Valuation Analysis

Bicara Therapeutics Inc. (BCAX) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.47x, versus the sector average of 2.75x.

At current multiples, Bicara Therapeutics Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Bicara Therapeutics Inc. Profitability — ROE, Margins, and Quality Score

Bicara Therapeutics Inc. (BCAX) earns a quality factor score of 27/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -29.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -27.4% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

BCAX Debt, Balance Sheet, and Financial Health

Bicara Therapeutics Inc. has a debt-to-equity ratio of 7.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.58x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $172M.

BCAX has a beta of 1.45, meaning it is more volatile than the broader market — a $10,000 investment in BCAX would be expected to move 44.8% more than the S&P 500 on any given day. The stability factor score for Bicara Therapeutics Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Bicara Therapeutics Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Bicara Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-2.52. Net income for the quarter was $-118M. Operating income came in at $-135M.

In FY 2025, Bicara Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-2.52. Net income for the quarter was $-138M. Operating income came in at $-156M.

In Q3 2025, Bicara Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.67. Net income for the quarter was $-36M. Operating income came in at $-41M.

In Q2 2025, Bicara Therapeutics Inc. reported revenue of $0 and earnings per share (EPS) of $-0.50. Net income for the quarter was $-27M. Operating income came in at $-32M.

Over the past 8 quarters, Bicara Therapeutics Inc. has experienced revenue contraction from $0 to $0. Investors analyzing BCAX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

BCAX Dividend Yield and Income Analysis

Bicara Therapeutics Inc. (BCAX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

BCAX Momentum and Technical Analysis Profile

Bicara Therapeutics Inc. (BCAX) has a momentum factor score of 62/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 2/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

BCAX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Bicara Therapeutics Inc. (BCAX) ranks #118 out of 838 stocks based on the Blank Capital composite score. This places BCAX in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing BCAX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full BCAX vs S&P 500 (SPY) comparison to assess how Bicara Therapeutics Inc. stacks up against the broader market across all factor dimensions.

BCAX Next Earnings Date

No upcoming earnings date has been announced for Bicara Therapeutics Inc. (BCAX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy BCAX? — Investment Thesis Summary

Bicara Therapeutics Inc. presents a balanced picture with arguments on both sides. The quality score of 27/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 62/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, Bicara Therapeutics Inc. (BCAX) earns a Hold rating with a composite score of 32.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on BCAX stock.

Related Resources for BCAX Investors

Explore more research and tools: BCAX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare BCAX head-to-head with peers: BCAX vs AZN, BCAX vs SLGL, BCAX vs VMD.